Switzerland has a strong biotech industry and continues to develop steadily. Just as the Bay Area is a key biotech cluster, so too is Switzerland in Europe. Interesting comparisons can be drawn and answers to new challenges can be examined by focusing on the biotech pipeline, financing rounds, and new companies in the industry. Where do these companies get their financing and how do they survive in difficult times? What can we learn from other successful clusters around the world?
Let’s discuss these ideas together. Join biotech companies, investors, start-up and spin-off candidates, academic-industry liasons, and others for a networking reception hosted by swissnex San Francisco and the Swiss Biotech Association during California’s Biotech Week.
5:15 pm doors open
5:30 pm welcome remarks from the Swiss Biotech Association and swissnex San Francisco, Heike Bihlmann and Hélène Montavon
5:45 pm BioBay Area and Swiss Biotech: a comparison, Patrik Frei, Venture Valuation
6:15 pm roundtable with Eric de la Fortelle, Delenex Therapeutics AG, Patrik Frei, Venture Valuation, Frédéric Lévy, Debiopharm SA, moderated by Heike Bihlmann, Swiss Biotech Association
6:45 pm reception and networking
9:00 pm doors close
The Swiss Biotech Association (SBA) represents more than 200 companies. SBA is the industry association of small and medium-sized enterprises active in all areas of biotechnology as well as a very good networking platform for the multinational companies active in the sector.